At its first appearance at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Ingersoll Rand underscored its transformation since the 2017 Gardner Denver IPO and 2020 acquisition of its namesake. The company reported fiscal 2025 revenue of $7.5 billion, EBITDA margins of 27%, and a free cash flow margin of approximately 17%. Management noted a market capitalization of $34 billion and total shareholder return exceeding 330% since 2017, positioning IR as a leader in mission-critical flow creation and life science solutions.

CEO Vicente Reynal and SVP Scott Watson outlined the Life Science Technologies platform as a core growth driver, leveraging over 80 established brands. The division aims to capitalize on robust demand for bioprocessing, clean-room air handling, and precision fluid management. Management highlighted recent contract wins in biopharma manufacturing and anticipates double-digit organic growth in this segment for fiscal 2026, supported by ongoing R&D investment and strategic partnerships with leading pharmaceutical firms.

Ingersoll Rand will publish its fourth quarter 2025 results on Thursday, February 12, 2026, after market close, followed by a live conference call at 8:00 a.m. Eastern Time on Friday, February 13. Investors may dial +1-888-330-3073 (domestic) or +1-646-960-0683 (international) using access code 8970061. A real-time webcast and replay will be available in the Events and Presentations section of the Ingersoll Rand Investor Relations website, where supplemental materials will be posted in advance.